Metronidazole in the treatment of non-specific vaginitis (NSV)

Br J Vener Dis. 1984 Jun;60(3):171-4. doi: 10.1136/sti.60.3.171.

Abstract

In a large multicentre study of 429 patients with the usual signs and symptoms of non-specific vaginitis (NSV), we studied the effect of different doses of metronidazole. The patients were divided into five treatment groups as follows: group A was given 400 mg metronidazole three times daily for seven days, group B 2000 mg as a single dose, group C 2000 mg on days 1 and 2, group D 2000 mg on days 1 and 3, and group E was given 1200 mg metronidazole once daily for five days. At follow up examination four weeks from the start of treatment, patients in groups D and E showed the best clinical results with cure rates of 94.0% and 93.6% respectively. In addition the rate of reisolation of Gardnerella vaginalis was lowest in group D. We therefore recommend metronidazole 2000 mg on days 1 and 3 as routine treatment for non-specific or vaginitis associated with gardnerella.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Clinical Trials as Topic
  • Drug Administration Schedule
  • Female
  • Gardnerella vaginalis / isolation & purification
  • Humans
  • Metronidazole / administration & dosage*
  • Metronidazole / therapeutic use
  • Middle Aged
  • Vaginitis / drug therapy*
  • Vaginitis / microbiology

Substances

  • Metronidazole